1. Search Result
Search Result
Results for "

serotonin release

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Fluorescent Dyes

2

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-172420

    GM-2505

    5-HT Receptor Neurological Disease
    Bretisilocin (GM-2505) is the agonist for 5-HT2A receptor and a serotonin releaser. Bretisilocin exhibits antidepressant activity and can be used in the study of depression .
    Bretisilocin
  • HY-100656

    Dopamine Receptor 5-HT Receptor Neurological Disease
    Desmethyl cariprazine is a major active metabolite of cariprazine, with activities at human dopamine receptors and serotonin receptors, showing a pEC50 of 8.90 at human D2 receptors, a pEC50 of 8.09 at D3 receptors, and a pEC50 of 6.28 at 5-HT1A receptors. Desmethyl cariprazine inhibits forskolin-induced cAMP production at D2, D3 and 5-HT1A receptors, and suppresses serotonin-induced Ca 2+ release at 5-HT2B receptors. Desmethyl cariprazine is applicable to research related to schizophrenia, bipolar disorder type I and bipolar disorder.
    Desmethyl cariprazine
  • HY-B1693
    Levomepromazine
    1 Publications Verification

    Methotrimeprazine

    5-HT Receptor Dopamine Receptor Histamine Receptor Autophagy Enterovirus Calcium Channel Infection Neurological Disease Inflammation/Immunology
    Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .
    Levomepromazine
  • HY-N7097

    Antibiotic Bacterial Infection
    Sulbenicillin disodium is a semisynthetic α-sulfonylbenzylpenicillin antibiotic. Sulbenicillin disodium exerts antibacterial activity against multiple gram-negative rods. Sulbenicillin disodium inhibits primary and secondary platelet aggregation, serotonin release from platelets, and platelet adherence via platelet surface coating. Sulbenicillin disodium can be used for the research of Pseudomonas aeruginosa, Pseudomonas maltophilia, and Pseudomonas cepacia infections .
    Sulbenicillin disodium
  • HY-D2335

    Fluorescent Dye Neurological Disease
    SERTlight is a fluorescent agent that can specifically label serotonergic neuronal cell bodies, dendrites, and axonal projections as fluorescent substrates of the serotonin transporter (SERT). SERTlight is orthogonal to various genetically encoded sensors in terms of optics, pharmacology, and operation, enabling multiple imaging. SERTlight allows the use of GRAB5HT sensors to label distal 5HT axonal projections and simultaneously image the release of endogenous 5HT, providing a new multifunctional molecular tool for studying serotonergic systems .
    SERTlight
  • HY-W100249

    5-Methoxy-6-methyl-2-aminoindan

    5-HT Receptor Neurological Disease
    MMAI is a selective serotonin releaser that can be used in the research of mental illnesses .
    MMAI
  • HY-106865

    Dopamine Receptor Adrenergic Receptor Cardiovascular Disease
    Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research .
    Mivazerol
  • HY-103465

    Monoamine Transporter Others
    FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 µM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
    FFN511
  • HY-18332C

    Serotonin Transporter Dopamine Transporter Neurological Disease
    DOV-216,303 (Free Base) is a potent triple serotonin, norepinephrine, and dopamine reuptake inhibitor, with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. Has antidepressant-like effects and increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
    DOV-216,303 Free Base
  • HY-156807

    Serotonin Transporter 5-HT Receptor Neurological Disease
    LY 367265 is a 5-hydroxytryptamine transporter (SERT) inhibitor (IC₅₀ = 3.1 nM) and a 5-HT₂A receptor antagonist (Kᵢ = 0.81 nM). LY 367265 has the inhibitory activity on the norepinephrine transporter (NET) of extremely weak (IC₅₀ > 1000 nM); it has low affinity for subtypes such as 5-HT₁B (Kᵢ = 490 nM) and 5-HT₁D (Kᵢ = 81 nM), showing high selectivity. LY 367265 concentration-dependently enhances of [³H]5-HT efflux (EC₅₀ = 250 nM). LY 367265 antagonizes the contraction response of Sumatriptan (HY-B0121B), indicating its functional antagonistic activity on 5-HT₁D-like receptors. LY 367265 can be used for the study of diseases such as anxiety disorders and post-traumatic stress disorder .
    LY 367265
  • HY-172071

    PAL-1046 hydrochloride

    5-HT Receptor Neurological Disease
    Methamnetamine (PAL-1046) hydrochloride is an amphetamine-based psychoactive substance. Methamnetamine hydrochloride causes excessive release of serotonin .
    Methamnetamine hydrochloride
  • HY-127023

    EPA-5-HT

    Endogenous Metabolite FAAH Interleukin Related Tyrosine Hydroxylase Metabolic Disease
    Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses IL-17 release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms .
    Eicosapentaenoyl serotonin
  • HY-116680

    5-HT Receptor Cardiovascular Disease Neurological Disease
    LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .
    LY53857
  • HY-19125

    Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease Inflammation/Immunology
    BN-50726 is a potent platelet-activating factor (PAF) receptor antagonist. BN-50726 inhibits PAF-induced effects (e.g., [3H]-serotonin release and hypotension) (IC50=5.40 nM). BN-50726 is promising for research of PAF-mediated pathological processes (e.g., inflammation, anaphylaxis, hypotension) .
    BN-50726
  • HY-120155

    Sigma Receptor iGluR Neurological Disease
    MS-377 is a selective and orally active sigma-1 receptor ligand (Ki=73 nM) with weak affinity for sigma-2 receptor (Ki=6900 nM) and no affinity for any other receptors including dopamine, serotonin, PCP site, glutamate, γ-aminobutylic acid, adenosine, adrenergic receptors, etc. (Ki: >10 μM). MS-377 indirectly modulates the NMDA receptor ion-channel complex. MS-377 is a antipsychotic agent. MS-377 inhibits PCP-induced behaviors by inhibition of the increase in dopamine and serotonin release in the rat medial prefrontal cortex. MS-377 can be used for research of schizophrenia .
    MS-377
  • HY-B1693A

    Methotrimeprazine hydrochloride

    5-HT Receptor Dopamine Receptor Histamine Receptor Autophagy Enterovirus Calcium Channel Infection Neurological Disease Inflammation/Immunology
    Levomepromazine (Methotrimeprazine) hydrochloride is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine hydrochloride has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine hydrochloride can induce adaptive ER stress and autophagy. In addition, Levomepromazine hydrochloride has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine hydrochloride can be used in the study psychiatric disorders and relieving nausea and vomiting .
    Levomepromazine hydrochloride
  • HY-B1693R

    Methotrimeprazine (Standard)

    Reference Standards 5-HT Receptor Dopamine Receptor Autophagy Histamine Receptor Enterovirus Calcium Channel Infection Neurological Disease Inflammation/Immunology
    Levomepromazine (Standard) is the analytical standard of Levomepromazine. This product is intended for research and analytical applications. Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .
    Levomepromazine (Standard)
  • HY-175721

    Serotonin Transporter Neurological Disease
    UCD0820 is a Serotonin transporter (SERT) inhibitor that acts as a partial serotonin releasing agent (SRA). UCD0820 can be used for depression, addiction and post-traumatic stress disorder (PTSD) research .
    UCD0820
  • HY-175720

    Serotonin Transporter Neurological Disease
    UCD0168 is a Serotonin transporter (SERT) inhibitor that acts as a full serotonin releasing agent (SRA). UCD0168 can be used for depression, addiction and post-traumatic stress disorder (PTSD) research .
    UCD0168
  • HY-W158945

    Serotonin Transporter Neurological Disease
    3-Chloroamphetamine hydrochloride is a derivative of Amphetamine that acts as a central nervous system stimulant by releasing serotonin and dopamine.
    3-Chloroamphetamine hydrochloride
  • HY-W342779

    Dopamine Receptor Neurological Disease
    4-Bromoamphetamine hydrochloride is an amphetamine derivative which acts as a serotonin-norepinephrine-dopamine releasing agent (SNDRA) and produces stimulant effects. 4-Bromoamphetamine hydrochloride is highly neurotoxic, producing long-term depletion of serotonin .
    4-Bromoamphetamine hydrochloride
  • HY-131556

    p-Iodoamphetamine hydrochloride

    5-HT Receptor Neurological Disease
    4-Iodoamphetamine (p-Iodoamphetamine) hydrochloride is a halogenated amphetamine featuring an iodine atom at the para position of the phenyl group. 4-Iodoamphetamine hydrochloride selectively induces serotonin release and inhibits reuptake by rat brain synaptosomes.
    4-Iodoamphetamine hydrochloride
  • HY-162511

    Dopamine Transporter Serotonin Transporter Others
    IP2015 is an inhibitor for monoamine reuptake, that inhibits the reuptake of dopamine, serotonin (5-HT), and noradrenaline. IP2015 increases release of central dopamine and peripheral nitric oxide (NO), causes the NO-mediated relaxation of erectile tissue, and thus induces erection in rat model .
    IP2015
  • HY-135222

    5-Methoxy-6-methyl-2-aminoindan hydrochloride

    5-HT Receptor Neurological Disease
    MMAI (5-Methoxy-6-methyl-2-aminoindan) hydrochloride is a selective serotonin releaser that does not produce psychoactive or hallucinogenic effects in the context of drug discrimination in rats. MMAI hydrochloride induces a behavioral syndrome in rats, including hypokinesia with freezing, spinning, Straub tail, flat posture, and reduced sleep time .
    MMAI hydrochloride
  • HY-W061043

    Serotonin Transporter Dopamine Transporter Neurological Disease
    DOV-216,303 is an antidepressant compound. DOV-216,303 inhibits the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. DOV-216,303 increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
    DOV-216,303
  • HY-133858

    5-HT Receptor Neurological Disease
    25N-NBOMe hydrochloride, a 2C-N derivative, is a 5-HT2A and 5-HT2C receptors agonist with Ki values of 0.144 nM and 1.06 nM, respectively. 25N-NBOMe hydrochloride has little to no efficacy at inducing release of preloaded neurotransmitter from recombinant dopamine, serotonin and norepinephrine transporters .
    25N-NBOMe hydrochloride
  • HY-111066

    Dopamine Receptor Others
    JNJ-37822681 is a fast dissociating D2 antagonist with activity in inhibiting schizophrenia. JNJ-37822681 has high specificity for D2 receptors and is effective in animal models, inducing increased levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibiting antidepressant activity in the mouse tail suspension test, while having a good brain distribution and lower prolactin release.
    JNJ-37822681
  • HY-103465B

    Monoamine Transporter Others
    FFN511 (hydrochloride) is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 (hydrochloride) inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 µM. FFN511 (hydrochloride) directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
    FFN511 hydrochloride
  • HY-116778

    Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Prostaglandin G2 is a prostaglandin peroxide. Prostaglandin G2 acts as a precursor for thromboxane A2 production, inducing platelet aggregation and serotonin release. Prostaglandin G2 also induces cerebral arteriole injury in anesthetized cats via the generation of reactive oxygen free radicals, triggering persistent vasodilation, reduced reactivity to hypocapnia, and endothelial damage. Prostaglandin G2 can be used in studies related to cerebral arteriole injury .
    Prostaglandin G2
  • HY-174146

    5-HT Receptor Neurological Disease
    5-HT1A agonist 1 (Compound Ex.37) is a highly selective 5-HT1a receptor agonist (EC50=0.18 nM). 5-HT1A agonist 1 mimicks serotonin binding to the receptor, promotes postsynaptic membrane hyperpolarization, inhibits neuronal hyperexcitability, and reduces the release of anxiety-related neurotransmitters. 5-HT1A agonist 1 is promising for research of neuropsychiatric diseases .
    5-HT1A agonist 1
  • HY-141554A

    (2S,3S,11bR)-DHTBZ

    Monoamine Transporter Neurological Disease
    (2S,3S,11bR)-Dihydrotetrabenazine ((2S,3S,11bR)-DHTBZ) is a highly selective inhibitor of vesicular monoamine transporter 2 (VMAT2) with a Ki value of 593 nM. (2S,3S,11bR)-Dihydrotetrabenazine inhibits vesicular transport of monoamine neurotransmitters like dopamine and serotonin, reducing their synaptic release. (2S,3S,11bR)-Dihydrotetrabenazine is promising for research of Huntington's chorea and other hyperkinetic disorders .
    (2S,3S,11bR)-Dihydrotetrabenazine
  • HY-111136

    GABA Receptor 5-HT Receptor Dopamine Receptor Histamine Receptor Neurological Disease
    BL-1020 mesylate is the mesylate salt form of BL-1020. BL-1020 mesylate is an antipsychotic agent. BL-1020 mesylate is inhibitor for dopamine receptor and serotonin receptor (5-HT receptor), with Ki of 0.066, 0.062 and 0.21 nM, for D2L, D2S and 5-HT2A receptors, respectively. BL-1020 mesylate is agonist for GABAA receptor with Ki of 3.74 μM, and enhances the GABA release. BL-1020 mesylate exhibits high affinity with histamine receptor (Ki is 0.47 nM). BL-1020 mesylate reduces Amphetamine-induced hyperactivity, with lower catalepsy and sedation. BL-1020 mesylate is blood-brain barrier penetrate .
    BL-1020 mesylate
  • HY-165395

    Phosphodiesterase (PDE) Inflammation/Immunology
    AY 25674 is an orally active antiallergic agent and a PDE inhibitor. AY 25674 inhibits the release of allergic histamine from mast cells. AY 25674 suppresses passive anaphylaxis induced by reaginic (IgE) antibodies. AY 25674 does not inhibit the increased vascular permeability caused by non-reaginic antibodies, serotonin or histamine. AY 25674 reaches its peak activity shortly after administration; rapid tolerance occurs at high doses. AY 25674 can be used in research related to passive anaphylaxis .
    AY 25674
  • HY-186169A

    5-HT Receptor Drug Isomer Neurological Disease
    S-MDDMA is the S-enantiomer of (R,S)-MDDMA (HY-186169B), and mediates serotonin release from cells expressing SERT .
    S-MDDMA
  • HY-186169B

    Serotonin Transporter Dopamine Transporter Neurological Disease
    (R,S)-MDDMA is an MDMA analog that lacks the psychostimulant effects of its parent compound. (R,S)-MDDMA still retains partial serotonin-releasing activity .
    (R,S)-MDDMA
  • HY-172763

    Drug Derivative Serotonin Transporter Dopamine Transporter 5-HT Receptor Neurological Disease
    EDMA hydrochloride is a derivative of MDMA. EDMA hydrochloride is a substrate for multiple neurotransmitter transporters, including serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET). EDMA hydrochloride has 5-HT releasing activity at SERT (EC50 = 117 nM) and MPP + releasing activity at DAT (EC50 = 597 nM) and NET (EC50 = 325 nM) .
    EDMA hydrochloride
  • HY-100656AS

    Isotope-Labeled Compounds Dopamine Receptor 5-HT Receptor Neurological Disease
    Desmethyl cariprazine-d8 is the deuterium labeled Desmethyl cariprazine (HY-100656). Desmethyl cariprazine is a major active metabolite of cariprazine, with activities at human dopamine receptors and serotonin receptors, showing a pEC50 of 8.90 at human D2 receptors, a pEC50 of 8.09 at D3 receptors, and a pEC50 of 6.28 at 5-HT1A receptors. Desmethyl cariprazine inhibits forskolin-induced cAMP production at D2, D3 and 5-HT1A receptors, and suppresses serotonin-induced Ca 2+ release at 5-HT2B receptors. Desmethyl cariprazine is applicable to research related to schizophrenia, bipolar disorder type I and bipolar disorder.
    Desmethyl cariprazine-d8
  • HY-103465R

    Reference Standards Monoamine Transporter Others
    FFN511 (Standard) is the analytical standard of FFN511 (HY-103465). This product is intended for research and analytical applications. FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 μM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
    FFN511 (Standard)
  • HY-166562S

    Methotrimeprazine-d6 hydrochloride

    Isotope-Labeled Compounds Enterovirus Histamine Receptor Autophagy 5-HT Receptor Calcium Channel Dopamine Receptor Infection Neurological Disease Inflammation/Immunology
    Levomepromazine-d6 hydrochloride (Methotrimeprazine-d6 hydrochloride) is the deuterium labeled Levomepromazine hydrochloride. Levomepromazine (Methotrimeprazine) hydrochloride is an orally active antipsychotic compound and Ca 2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca 2+ levels. Levomepromazine hydrochloride has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine hydrochloride can induce adaptive ER stress and autophagy. In addition, Levomepromazine hydrochloride has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine hydrochloride can be used in the study psychiatric disorders and relieving nausea and vomiting .
    Levomepromazine-d6 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: